O-acetyltetrahydroberberrubine | 2748-62-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: O-acetyltetrahydroberberrubine
• 英文别名: (17-Methoxy-5,7-dioxa-13-azapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15(20),16,18-hexaen-16-yl) acetate
• CAS: 2748-62-1
• 化学式: C₂₁H₂₁NO₅
• 分子量: 367.401
• InChiKey: GLRJJXPRWYHFGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  57.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  O-acetyltetrahydroberberrubine 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以13 mg的产率得到(+/-)-nandinine
  参考文献：
  名称：

  Berberis alkaloids. XVII. Investigation of the alkaloids of Berberis heteropoda

  摘要：

  DOI：

  10.1007/bf00631012
• 作为产物：
  描述：

  盐酸小檗碱 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 4.25h， 生成 O-acetyltetrahydroberberrubine
  参考文献：
  名称：

  化学和微生物半合成四氢小ber碱抑制组织因子促凝活性

  摘要：

  为了发现对组织因子促凝活性的新抑制剂，在脂多糖刺激的人THP-1细胞模型上筛选了21种四氢小ber碱。化合物：在这些四氢原小檗碱，几个独特的化合物是通过微生物转化合成6（升-corydalmine）通过区域选择性脱甲基化，得到灰色链霉菌ATCC 13273，而化合物4A，4B，5H和5I由分别微生物糖基化产物粘帚deliquescens NRRL1086。生物测定结果表明，化合物3（四氢小ber碱），10（四氢小rub碱）和5f（5的肉桂酸酯）和5i（5的糖苷产物）表现出最大的潜在作用，IC 50值分别为8.35、6.75、3.75和8.79 nM。初步的结构和活性关系分析表明，A环的2，3-亚甲基二氧基是强抑制作用所必需的，手性中心C-14的R构型比S型产物具有更高的活性。化合物5的脂肪酸或芳香酸酯的形成，除了肉桂酸酯，将削弱其作用。还有趣的是注意到四氢小ber碱的糖基化将保持甚至增强抑

  DOI：

  10.1016/j.bmc.2012.11.002

文献信息

• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA NASH, DE LA NAFLD ET DE L'OBÉSITÉ
  申请人：LIU JINGWEN

  公开号：WO2021067490A1

  公开（公告）日：2021-04-08

  The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

  目前的技术涉及使用I、II、III、IV、V和/或VI式化合物治疗NASH、NAFLD和/或肥胖的方法。这些方法包括向患有非酒精性脂肪肝炎（NASH）、非酒精性脂肪肝病（NAFLD）和/或肥胖的受试者施用这种化合物的治疗有效剂量。
• COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS
  申请人：Liu Haiyan

  公开号：US20090048246A1

  公开（公告）日：2009-02-19

  Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and activate AMP-activated protein kinase. Specific stereoisomers of Corydalis compounds with lipid lowering activity include 14R-(+)-corypalmine, 14R,13S-(+)-corydaline, 14R-(+)-tetrahydropalmatin, (+)-corlumidin, d-(+)-bicuculline, and (+)-egenine.

  从黄堇属植物提取物或分离纯化的化合物构成的组合物可预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。黄堇化合物及其天然和合成来源的衍生物可降低总胆固醇、LDL-胆固醇和甘油三酯，增加肝LDL受体表达并激活AMP激活蛋白激酶。具有降脂活性的黄堇化合物的特定立体异构体包括14R-(+)-可丹碱、14R,13S-(+)-可丹啉、14R-(+)-四氢棕榈碱、(+)-可鲁米丁、d-(+)-比库枯碱和(+)-艾根碱。
• [EN] CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS<br/>[FR] DÉRIVÉS DE CORYDALINE UTILES DANS LA RÉDUCTION DES TAUX LIPIDIQUES
  申请人：CVI PHARMACEUTICALS LTD

  公开号：WO2010075469A1

  公开（公告）日：2010-07-01

  The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.

  目前的技术涉及到公式（V）和（VI）的化合物以及制备和使用这些化合物的方法。使用方法包括预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。本文披露的化合物还能降低总胆固醇、LDL-胆固醇和甘油三酯，增加肝LDL受体表达，抑制PCSK9表达，并激活AMP激活的蛋白激酶。
• Methods and compositions for the treatment of metabolic syndrome
  申请人：Lippa S. Arnold

  公开号：US20080081781A1

  公开（公告）日：2008-04-03

  Methods and compositions containing a berberine compound or berberine related or proto-berberine or derivative compound are provided for the prevention and treatment of metabolic and cardiovascular disorders including metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol. Additional compositions and methods are provided which employ a berberine compound or berberine related or derivative compound in combination with a second anti-therapeutic agent to yield more effective treatment tools against metabolic disorders, and/or dual activity therapeutic methods and formulations useful to prevent or reduce hyperlipidemia and/or hyperglycemia and one or more causal or related symptoms or conditions associated with hyperlipidemia and/or hyperglycemia in mammalian subjects.
• Methods And Compositions For The Treatment of Hyperlipidemia
  申请人：Jiang Jian-Dong

  公开号：US20110158932A1

  公开（公告）日：2011-06-30

  Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma. Additional compositions and methods are provided which employ a berberine compound or berberine related or derivative compound in combination with a second anti-hyperlipidemia agent, or a different therapeutic agent to yield more effective treatment tools against hyperlipidemia and/or cardiovascular disease, and/or dual activity therapeutic methods and formulations useful to prevent or reduce hyperlipidemia and one or more causal or related symptoms or conditions associated with hyperlipidemia in mammalian subjects.